Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Africa

- PMLiVE

Dexcom and Fitbit team up to tackle diabetes management

Will develop a wearable blood glucose tracking product

- PMLiVE

Lilly mulls divestment of its animal health operations

Pharma firm is due to make a final decision on Elanco in 2018

- PMLiVE

AZ gets US green light for new Bydureon formulation

Its latest injectable suspension proven to reduce blood sugar levels

Lilly strengthens team with in-house promotions

And two senior leaders retire

- PMLiVE

J&J seeks US OK to add CV claim to Invokana label

If approved the treatment could better compete with rivals Jardiance and Victoza

Eli Lilly HQ

Lilly gets early US approval for Ibrance rival abemaciclib

The breast cancer treatment, marketed as Verzenio, will also compete with Novartis' Kisqali

Eli Lilly HQ

Lilly’s abemaciclib data leaves potential uncertain

MONARCH 3 trial showed similar results to Pfizer’s Ibrance and Novartis’ Kisqali

Eli Lilly HQ

Lilly planning early re-file for JAK inhibitor baricitinib

The arthritis treatment could reach US market a year earlier than expected

- PMLiVE

Novo’s semaglutide beats Lilly’s Trulicity in diabetes contest

Analysts predict the drug could be worth $8.7bn in the next five years

- PMLiVE

Type 2 diabetes market set to soar to $64bn by 2026

Rising prevalence, progressive nature and diagnosis of the condition behind the surge

Eli Lilly HQ

Baricitinib delay casts a pall over Lilly’s results update

FDA requests further data that could keep the drug off the market for a couple of years

Eli Lilly HQ

Lilly pays Nektar $150m upfront for phase I autoimmune drug

Will add another $250m if candidate meets development objectives

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links